-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I07Eh1WniBZyfyHy2wj/9rwPEcMTNypVEjUwu8CoHa4rUEpGcnf0UzX1vnXGYQ8B XXki6nbbT8V0OWpgZjAKIA== 0001201800-07-000115.txt : 20070716 0001201800-07-000115.hdr.sgml : 20070716 20070716152912 ACCESSION NUMBER: 0001201800-07-000115 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070710 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20070716 DATE AS OF CHANGE: 20070716 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VASOMEDICAL INC CENTRAL INDEX KEY: 0000839087 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 112871434 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-18105 FILM NUMBER: 07981374 BUSINESS ADDRESS: STREET 1: 180 LINDEN AVENUE CITY: WESTBURY STATE: NY ZIP: 11590 BUSINESS PHONE: 5169974600 MAIL ADDRESS: STREET 1: 150 MOTOR PARKWAY STREET 2: SUITE 408 CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /DE/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: FUTURE MEDICAL PRODUCTS INC /NY/ DATE OF NAME CHANGE: 19920506 8-K 1 vaso8kenlan7-07.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 10, 2007 (Date of earliest event reported) VASOMEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 0-18105 11-2871434 -------- ------- ------------ (State or other (Commission File (IRS Employer jurisdiction of incorporation) Number) Identification No.) 180 Linden Avenue, Westbury, New York 11590 - ------------------------------------------------------------------------- (Address of principal executive offices) (zip code) Registrant's telephone number, including area code (516) 997-4600 ------------- ------------------------------------------------- (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act [ ] Pre-commencement communications pursuant to Rule 13e-4c under the Exchange Act (17 CFR 240.13e-4c) Item 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS (b) On July 10, 2007, Thomas Glover resigned as a director of the Company. Mr. Glover will continue to act as a consultant to the Company. (d) On July 10, 2007, the Board of Directors appointed Dr. Derek Enlander and Behnam Movaseghi as Directors. Dr. Enlander will also be serving on the Compensation Committee. Dr. Enlander, a Diplomate of the subdivision of Internal Medicine of the American Board of Nuclear Medicine, has been, since 1983, in private practice as well as an Attending Physician on the Faculty of Medicine at Mount Sinai Medical Center in New York City. He is also a Director of the New York CFIDS Center since 1983. He was an Assistant Professor at Columbia University from 1976-1980. From 1980-1983, Dr. Enlander was the Associate Director of the Division of Nuclear Medicine at NYU. Dr. Enlander is the author of numerous books and academic papers. Mr. Behnam Movaseghi is a Certified Public Accountant and has been Treasurer and Chief Financial Officer of Kerns Manufacturing Corporation since 1990. For approximately ten years prior therto, Mr. Movaseghi was a tax and financial consultant. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VASOMEDICAL, INC. Date: July 16, 2007 By: /s/ John C. K. Hui ------------------------------------- John C. K. Hui President and Chief Executive Officer -----END PRIVACY-ENHANCED MESSAGE-----